林业发展局批准用于皮肤癌的Unloxcyt,这是用于此用途的第一个PD-L1阻塞器。 FDA approves Unloxcyt for advanced skin cancer, first PD-L1 blocker for this use.

美国食品和药物管理局批准了Checkpoint Therapeutics公司的Unloxcyt (cosibelimab- ipdl) 用于治疗转移性或局部发达的皮肤状细胞癌,患者无法接受治疗性手术或放射治疗. The FDA has approved Unloxcyt (cosibelimab-ipdl) by Checkpoint Therapeutics for treating metastatic or locally advanced cutaneous squamous cell carcinoma in patients ineligible for curative surgery or radiation. 这是为这一用途批准的第一个PD-L1阻塞抗体。 It is the first PD-L1 blocking antibody approved for this use. 常见的副作用包括疲劳、肌肉骨骼疼痛、皮疹和腹泻。 Common side effects include fatigue, musculoskeletal pain, rash, and diarrhea. 药物每三周静脉注射一次。 The drug is administered intravenously every three weeks.